Results 151 to 160 of about 569,881 (316)
Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment
This review focuses on biomimetic nanomedicines for tumor microenvironment (TME) remodeling, covering their diverse biomimetic types, design principles, and mechanisms of immune cell reprogramming and reversal of immunosuppressive microenvironments, with particular emphasis on their application in synergistic immunotherapy.
Wanrong Wang +7 more
wiley +1 more source
Regulatory T cells (Tregs) suppress antitumor immunity. This study identifies that the translation scaffold DAP5/eIF4G2 is upregulated in tumor‐infiltrating Tregs (ti‐Tregs). DAP5 mediates an alternate translation mode to sustain CD25 and MCL‐1 expression, which is critical for ti‐Treg stability and survival in the tumor microenvironment.
Xiaojiang Lai +12 more
wiley +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
In hypoxic microenvironment, WNT5A is predominantly secreted by tumor‐associated macrophages. Hypoxia‐induced WTAP mediates ROR1 stability by m6A modifications in a HuR‐dependent manner in Glioma stem cells (GSCs). WNT5A activates the WNT pathway via ROR1 binding on GSCs, driving glioma‐derived endothelial cells (GDECs) differentiation.
Xiaoyong Chen +15 more
wiley +1 more source
This review outlines association between vasculitis and malignancies and provides practical value for clinicians in distinguishing primary vasculitis from malignancy‐associated forms and optimizing patient surveillance, improving recognition of tumor‐associated vasculitis to reduce the risk of misdiagnosis, supporting more accurate clinical decision ...
Xiaofei Shi +8 more
wiley +1 more source
Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. [PDF]
Activating mutations in FLT3 confer poor prognosis for individuals with acute myeloid leukemia (AML). Clinically active investigational FLT3 inhibitors can achieve complete remissions but their utility has been hampered by acquired resistance and ...
He, Bai-Liang +9 more
core
Dual Aptamers‐Based SETDB1 PROTACs as Effective Anti‐Tumor Strategies for Breast Cancer
This study establishes dual‐aptamer PROTACs targeting SETDB1 using a SETDB1‐specific aptamer conjugated to AS1411. The designed PROTACs penetrate cells, recruit MDM2 to degrade SETDB1, and inhibit cancer cell proliferation and migration. Remarkably, they also overcome tamoxifen resistance and enhance CD8+ T cell cytotoxicity, suppressing tumor growth ...
Yanxuan Guo +6 more
wiley +1 more source
Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo +5 more
wiley +1 more source
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély +5 more
wiley +1 more source

